Longeveron (LGVN) Interest Coverage Ratio Growth (1y) (2021 - 2026)
Longeveron (LGVN) Interest Coverage Ratio Growth (1y) (2021 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | -60.44% |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -347.04% |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 787.12% |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 53.59% |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | -32.04% |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | 73.00% |
| 10 | Longeveron | 15.18 Bn | 15.16 Bn | 264,000.00 | -57.40% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -57.40% |
| Dec 31, 2025 | -42.67% |
| Sep 30, 2025 | 76.01% |
| Jun 30, 2025 | 94.87% |
| Mar 31, 2025 | 78.42% |
| Dec 31, 2024 | 97.47% |
| Sep 30, 2024 | 9.92% |
| Jun 30, 2024 | -210.28% |
| Mar 31, 2024 | -14,612.45% |
| Dec 31, 2023 | -140.18% |
| Sep 30, 2023 | 0.50% |
| Jun 30, 2023 | -299.15% |
| Mar 31, 2023 | 97.43% |
| Dec 31, 2022 | 529,957.65% |
| Sep 30, 2022 | -8,397.71% |
| Jun 30, 2022 | -1,681.75% |
| Mar 31, 2022 | -2,137.02% |
| Dec 31, 2021 | 100.02% |
| Sep 30, 2021 | 99.63% |
| Jun 30, 2021 | 99.72% |